LivaNova price to free cash flow LIVN

Market value divided by free cash flow over the last twelve months, since 2017.

Today, Oct 23, 2026: 30.1×
10-year median: 52.2×
Against its 10-year history: 25th; percentile: 0 is its lowest day, 100 its highest
10-year range: 13.6× to 369×
Peer median: 20.7×

LivaNova's price to free cash flow is 30.1× as of Oct 23, 2026.

That is below its ten-year median of 52.2×, lower than on 75% of days in the last ten years.

Over that time it ranged from 13.6× in Apr 2025 to 369× in Jun 2021.

The median for 6 medical device stocks of a similar size is 20.7×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	30.1×	17.3×	30.5×
2025	17.9×	13.6×	25.0×
2024	23.3×	23.3×	364×
2023	329×	43.7×	330×
2022	49.8×	36.5×	68.5×
2021	57.0×	52.2×	369×
2020	n/m a value too high to mean anything
2019	189×	39.2×	217×
2018	52.8×	48.3×	118×
2017	47.7×	34.8×	52.5×

Against its peers

Companies in Medical - Devices nearest LivaNova's size, closest first, today.

Company	Price to free cash flow
LIVNLivaNova	30.1×
ITGRInteger	38.4×
TMDXTransMedics	31.0×
CNMDCONMED	11.0×
ZBHZimmer Biomet	12.3×
DXCMDexCom	20.9×
GEHCGE HealthCare Technologies	20.4×
Peer median	20.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on LivaNova

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.